Evidence map›Paper›PMID 34162893›Full record

ArticleScientific reports2021

A novel computer-aided diagnostic system for accurate detection and grading of liver tumors.

Ahmed Alksas, Mohamed Shehata, Gehad A Saleh, Ahmed Shaffie, Ahmed Soliman, Mohammed Ghazal, Adel Khelifi, Hadil Abu Khalifeh, Ahmed Abdel Razek, Guruprasad A Giridharan and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 55 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Effective Tumor Annotation for Automated Diagnosis of Liver Cancer.IEEE journal of translational engineering in health and medicine · 2025
    Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. A Novel System for Precise Grading of Glioma.Bioengineering (Basel, Switzerland) · 2022
    Article
  15. Review
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Ahmed Alksas *BioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA.
Mohamed Shehata *BioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA.
Gehad A Saleh *Department of Radiology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Ahmed ShaffieBioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA.
Ahmed SolimanBioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA.
Mohammed GhazalCollege of Engineering, Abu Dhabi University, Abu Dhabi, UAE.
Adel KhelifiComputer Science and Information Technology, Abu Dhabi University, Abu Dhabi, UAE.
Hadil Abu KhalifehCollege of Engineering, Abu Dhabi University, Abu Dhabi, UAE.
Ahmed Abdel RazekDepartment of Radiology, Faculty of Medicine, Mansoura University, Mansoura, 35516, Egypt.
Guruprasad A GiridharanBioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA.
Ayman El-BazBioImaging Lab, Department of Bioengineering, University of Louisville, Louisville, KY, 40292, USA. aselba01@louisville.edu.
University of Louisville · USAbu Dhabi University · AEMansoura University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is a major cause of morbidity and mortality in the world. The primary goals of this manuscript are the identification of novel imaging markers (morphological, functional, and anatomical/textural), and development of a computer-aided diagnostic (CAD) system to accurately detect and grade liver tumors non-invasively. A total of 95 patients with liver tumors (M = 65, F = 30, age range = 34-82 years) were enrolled in the study after consents were obtained. 38 patients had benign tumors (LR1 = 19 and LR2 = 19), 19 patients had intermediate tumors (LR3), and 38 patients had hepatocellular carcinoma (HCC) malignant tumors (LR4 = 19 and LR5 = 19). A multi-phase contrast-enhanced magnetic resonance imaging (CE-MRI) was collected to extract the imaging markers. A comprehensive CAD system was developed, which includes the following main steps: i) estimation of morphological markers using a new parametric spherical harmonic model, ii) estimation of textural markers using a novel rotation invariant gray-level co-occurrence matrix (GLCM) and gray-level run-length matrix (GLRLM) models, and iii) calculation of the functional markers by estimating the wash-in/wash-out slopes, which enable quantification of the enhancement characteristics across different CE-MR phases. These markers were subsequently processed using a two-stages random forest-based classifier to classify the liver tumor as benign, intermediate, or malignant and determine the corresponding grade (LR1, LR2, LR3, LR4, or LR5). The overall CAD system using all the identified imaging markers achieved a sensitivity of 91.8%±0.9%, specificity of 91.2%±1.9%, and F[Formula: see text] score of 0.91±0.01, using the leave-one-subject-out (LOSO) cross-validation approach. Importantly, the CAD system achieved overall accuracies of [Formula: see text], 85%±2%, 78%±3%, 83%±4%, and 79%±3% in grading liver tumors into LR1, LR2, LR3, LR4, and LR5, respectively. In addition to LOSO, the developed CAD system was tested using randomly stratified 10-fold and 5-fold cross-validation approaches. Alternative classification algorithms, including support vector machine, naive Bayes classifier, k-nearest neighbors, and linear discriminant analysis all produced inferior results compared to the proposed two stage random forest classification model. These experiments demonstrate the feasibility of the proposed CAD system as a novel tool to objectively assess liver tumors based on the new comprehensive imaging markers. The identified imaging markers and CAD system can be used as a non-invasive diagnostic tool for early and accurate detection and grading of liver cancer.

Indexed as

Diagnosis, Computer-AssistedAlgorithmsHumansImaging, Three-DimensionalLiver NeoplasmsMagnetic Resonance ImagingNeoplasm GradingProbability

Identifiers

PMID34162893
PMCPMC8222341
OpenAlexW3174241815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.